Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Innovation Council · Running

NEOpTTL Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement

Coordinator
Neogap Therapeutics AB, Sweden
Runs
1 November 2023 to 31 July 2026
Status
Running
EU funding
€2.5m
Total cost
€8.4m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190185439

What the project is doing

In the project's own words, from its summary on CORDIS.

NEOGAP has developed a groundbreaking personalised adoptive T cell therapy for treating solid tumours based on two proprietary technologies: PIOR® machine learning software and EpiTCer®. This cancer immunotherapy consists of producing personalised Tumour Trained Lymphocytes (pTTL), which are autologous T-cells harvested from regional lymph nodes, subjected to a neoantigen-driven T-cell stimulation technology to deliver highly tumour-reactive T-cell clones (pTTLs). pTTLs are re-infused to the patient where they infiltrate and kill cancer cells, leaving healthy cells untouched.

The therapy is broadly applicable to many cancer types, being personalised to each individual patient. In this EIC accelerator project, NEOGAP plans to complete the Phase 1b part of the first in human clinical trial of the therapy in advanced colorectal cancer patients, focused on safety assessment and biomarker exploration and optimise the manufacturing process for the next clinical studies.

Topics

Who is involved

OrganisationCityCountryRole
Neogap Therapeutics ABStockholmSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI